| Literature DB >> 35529977 |
Lamia Boubakri1, A Chakchouk-Mtibaa2, Abdullah S Al-Ayed3, L Mansour4, Nael Abutaha4, Abdel Halim Harrath4, L Mellouli2, I Özdemir5, S Yasar5, Naceur Hamdi1,3.
Abstract
A series of ruthenium(ii) complexes with N-heterocyclic carbene ligands were successfully synthesized by transmetalation reactions between silver(i) N-heterocyclic carbene complexes and [RuCl2(p-cymene)]2 in dichloromethane under Ar conditions. All new compounds were characterized by spectroscopic and analytical methods. These ruthenium(ii)-NHC complexes were found to be efficient precatalysts for the transfer hydrogenation of ketones by using 2-propanol as the hydrogen source in the presence of KOH as a co-catalyst. The antibacterial activity of ruthenium N-heterocyclic carbene complexes 3a-f was measured by disc diffusion method against Gram positive and Gram-negative bacteria. Compounds 3d exhibited potential antibacterial activity against five bacterial species among the six used as indicator cells. The product 3e inhibits the growth of all the six tested microorganisms. Moreover, the antioxidant activity determination of these complexes 3a-f, using 2,2-diphenyl-1-picrylhydrazyl (DPPH) and 2,2'-azinobis-3-ethylbenzothiazoline-6-sulphonic acid (ABTS) as reagent, showed that compounds 3b and 3d possess DPPH and ABTS antiradical activities. From a concentration of 1 mg ml-1, these two complexes presented a similar scavenging activity to that of the two used controls gallic acid (GA) and butylated hydroxytoluene (BHT). From a concentration of 10 mg ml-1, the percentage inhibition of complexes 3b and 3d was respectively 70% and 90%. In addition, these two Ru-NHC complexes exhibited antifungal activity against Candida albicans. Investigation of the anti-acetylcholinesterase activity of the studied complexes showed that compounds 3a, 3b, 3d and 3e exhibited good activity at 100 μg ml-1 and product 3d is the most active. In a cytotoxicity study the complexes 3 were evaluated against two human cancer cell lines MDA-MB-231 and MCF-7. Both 3d and 3e complexes were found to be active against the tested cell lines showing comparable activity with examples in the literature. This journal is © The Royal Society of Chemistry.Entities:
Year: 2019 PMID: 35529977 PMCID: PMC9074002 DOI: 10.1039/c9ra05605j
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Scheme 1Synthesis of ruthenium–NHC carbene complexes (3a–f).
Fig. 1Structure of ruthenium–NHC carbene complexes 3(a–f).
Fig. 21H NMR spectra of Ru(ii)–N-heterocyclic carbene complexes 3a (CDCl3, 300 MHz).
Fig. 313C NMR spectra of Ru(ii)–N-heterocyclic carbene complexes 3a (CDCl3, 75 MHz).
Fig. 4DART-TOF-MS of Ru(ii)–N-heterocyclic carbene complexes 3a.
Scheme 2Mechanism of fragmentation leading to peaks m/z = 225.
Transfer hydrogenation of ketones catalyzed by ruthenium–NHC complexes 3(a–c)a
|
| ||||
|---|---|---|---|---|
| Entry | Substrate | Catalyst | Product | Yield |
| 1 |
| 3a |
| 56 |
| 2 | 3b | 45 | ||
| 3 | 3c | 60 | ||
| 4 |
| 3a |
| 64 |
| 5 | 3b | 48 | ||
| 6 | 3c | 57 | ||
| 7 |
| 3a |
| 35 |
| 8 | 3b | 25 | ||
| 9 | 3c | 40 | ||
| 10 |
| 3a |
| 32 |
| 11 | 3b | 15 | ||
| 12 | 3c | 28 | ||
| 13 |
| 3a |
| 70 |
| 14 | 3b | 64 | ||
| 15 | 3c | 66 | ||
Reaction conditions: 0.005 mmol Ru–NHC, i-PrOH (5 ml), KOH (2 mmol), substrate (0.5 mmol), 80 °C, 1 h.
Conversions are based on corresponding ketones.
Fig. 5Zone of inhibition of Ru–NHC complexes (3a–f).
Fig. 6The method of determining the MIC.
Antibacterial activity of the synthesized Ru–NHC complexes (3a–f)
| Compounds | Microorganism indicator | |||||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
| LB 14110 | ATCC 19117 | ATCC 6538 | ATCC 14028 | ATCC 49189 | ||
| 3a | 30 ± 0.5 | 16 ± 0.2 | — | 16 ± 0.2 | — | — |
| 3b | 20 ± 0.4 | — | — | — | 20 ± 0.2 | — |
| 3c | 18 ± 0.2 | 20 ± 0.4 | — | 14 ± 0.7 | — | — |
| 3d | 30 ± 0.32 | 18 ± 0.1 | 22 ± 0.4 | 18 ± 0.1 | 26 ± 0.11 | — |
| 3e | 23 ± 0.3 | 16 ± 0.5 | 17 ± 0.3 | 16 ± 0.6 | 16 ± 0.22 | 15 ± 0.2 |
| 3f | — | — | — | — | — | — |
Minimum Inhibitory Concentrations (MICs) expressed in mg ml−1
| Compounds | Minimum inhibitory concentrations (mg ml−1) | ||
|---|---|---|---|
|
|
|
| |
| LB 14110 | ATCC 19117 | ATCC 14028 | |
| 3a | 0.039 | 0.3125 | 2.5 |
| 3b | 0.625 | 5 | 5 |
| 3c | 0.039 | 1.25 | 2.5 |
| 3d | 0.0195 | 0.1562 | 0.0781 |
| 3e | 0.0195 | 0.0781 | 1.25 |
| 3f | — | — | — |
| Ampicillin | 0.004 | 0.002 | 0.625 |
Fig. 7Scavenging activity of compounds 3b and 3d on DPPH radicals.
Fig. 8Percent inhibition of complexes 3b and 3d as a function of concentration.
Fig. 9Antifungal activity against Candida albicans.
Minimum Inhibitory Concentrations (MICs) expressed in mg ml−1
| Strain | Compounds | |||||
|---|---|---|---|---|---|---|
| 3a | 3b | 3c | 3d | 3e | 3f | |
|
| — | 22 ± 0.5 | — | 34 ± 0.18 | — | — |
Acetylcholinesterase inhibitory activity (AChEI) (%) of compounds (3a–f)
| Compounds | 3a | 3b | 3c | 3d | 3e | 3f |
|---|---|---|---|---|---|---|
| (AChEI) (%) | 32.8 | 45.3 | — | 47.1 | 38 | — |
Anticancer and antimicrobial profile of synthesized Ru–NHC complexes (3a–f)
| Compounds | Anticancer activity IC50 in μg ml−1 | Antimicrobial activity (50 μg per disc) | |||
|---|---|---|---|---|---|
| MCF7 | MDA-MB-231 |
|
|
| |
| 3a | 4.2 ± 3.6 | 2.5 ± 4.3 | 21.0 ± 1 | 22.5 ± 2.5 | 25.0 ± 00 |
| 3b | 3.1 ± 3.1 | 2.6 ± 5.9 | 23.3 ± 1.5 | 25.5 ± 1.5 | 28.5 ± 1.5 |
| 3c | 1.7 ± 3.1 | 16 ± 2.8 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 |
| 3d | 0.6 ± 1.8 | 3.1 ± 00 | 25.0 ± 00 | 25.5 ± 0.5 | 30.5 ± 0.5 |
| 3e | 0.68 ± 3.2 | 1.93 ± 2.6 | 100.0 ± 2.0 | 11.0 ± 1.0 | 10.0 ± 0 |
| 3f | 1.3 ± 4.1 | 3.3 ± 2.9 | 12.0 ± 1.0 | 13.0 ± 00 | 13.0 ± 00 |
| Tetracycline | NT | NT | 22 ± 0.3 | 25.5 | 0.0 ± 00 |